Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT05924997 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: adebrelimab, camrelizumab plus apatinib

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University